KDR and neoplasm: Importantly, as VEGFR-1 plays a critical role in tumor-associated angiogenesis but not in physiological angiogenesis, VEGFR-1-blocking therapies are expected to cause less adverse effects than molecules targeting VEGFR-2 [66,67].